Market Price

44.90 

0.71 1.6%

as of Mar 05 '21

52 Week Range:

19.35 55.33


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug, that in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; and AMG424, a bispecific CD38 x CD3 preclinical candidate for various myeloma. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104, which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. to develop and commercialize bispecific and other Fc engineered antibody drug candidates using its proprietary XmAb technologies and drug candidates, as well as MorphoSys Ag to develop and commercialize bispecific antibody product candidates; license agreement with Amgen Inc. to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc.was founded in 1997 and is headquartered in Monrovia, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) -2.39
1.90
3.78
4.35
6.18
9.46
10.72
9.82
growth rate 100.0% 99.0% 15.1% 42.1% 53.1% 13.3% -8.4%
Earnings BIT -11.20
-8.59
-58.30
-15.95
-17.09
44.40
-42.73
-79.13
14.05
-76.26
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0% 100.0% -100.0%
Avg.PE 1.69
-6.25
-6.25
26.77
-22.93
-22.93
-22.93
-22.93
growth rate -100.0% 0.0% 100.0% -100.0% 0.0% 0.0% 0.0%
ROA -50.07
-50.50
170.76
-21.17
-12.81
7.44
-11.95
-14.56
4.31
-10.10
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% -100.0% 0.0% 100.0% -100.0%
ROE -24.73
-15.87
9.92
-16.42
-17.52
4.82
-11.90
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% -100.0%
ROIC -24.76
-17.52
9.08
-17.81
-19.78
4.73
-12.90
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% -100.0%
Cur. Ratio 0.56
0.11
10.44
9.32
2.25
1.33
2.28
5.86
8.39
5.27
growth rate -80.4% 9,390.9% -10.7% -75.9% -40.9% 71.4% 157.0% 43.2% -37.2%
Quick Ratio 0.56
0.10
10.43
9.30
2.22
1.31
2.22
5.67
8.29
5.18
growth rate -82.1% 10,330.0% -10.8% -76.1% -41.0% 69.5% 155.4% 46.2% -37.5%
Leverage 1.19
1.14
1.27
1.37
1.38
1.11
1.13
1.23
growth rate -4.2% 11.4% 7.9% 0.7% -19.6% 1.8% 8.9%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 0.03
0.35
0.10
2.97
0.04
8.62
1.14
10.99
22.08
23.94
growth rate 1,120.7% -71.8% 2,866.0% -98.5% 19,481.8% -86.8% 862.4% 100.9% 8.5%
Acct.Payable 2.66
2.60
2.60
1.69
6.40
3.88
6.87
3.80
10.19
8.95
growth rate -2.3% 0.0% -35.0% 278.5% -39.4% 77.0% -44.7% 168.3% -12.1%
Cur.Assets 14.65
2.84
78.10
57.75
97.68
141.65
230.88
315.73
558.41
637.67
growth rate -80.6% 2,651.0% -26.1% 69.1% 45.0% 63.0% 36.8% 76.9% 14.2%
Total Assets 22.37
11.66
87.30
67.82
206.91
428.56
390.20
576.73
670.25
703.24
growth rate -47.9% 648.8% -22.3% 205.1% 107.1% -9.0% 47.8% 16.2% 4.9%
Cash 14.54
2.31
78.00
54.65
12.59
14.53
16.53
26.25
50.31
163.54
growth rate -84.1% 3,273.7% -29.9% -77.0% 15.4% 13.8% 58.8% 91.7% 225.1%
Cur.Liabilities 26.20
25.48
7.50
6.20
43.43
106.29
72.65
53.85
66.56
121.06
growth rate -2.7% -70.6% -17.4% 600.9% 144.7% -31.7% -25.9% 23.6% 81.9%
Liabilities 33.31
31.16
13.80
8.53
44.48
114.61
73.74
55.05
77.05
130.80
growth rate -6.5% -55.7% -38.2% 421.3% 157.7% -35.7% -25.3% 40.0% 69.8%
LT Debt 0.01
0.00
0.00
0.00
0.00
growth rate -100.0%
Equity 73.50
59.29
162.43
313.95
316.46
521.68
593.20
572.44
growth rate -19.3% 174.0% 93.3% 0.8% 64.9% 13.7% -3.5%
Common Shares 17.00
17.00
16.00
31.00
39.00
42.00
47.00
54.00
58.00
57.00
growth rate 0.0% -5.9% 93.8% 25.8% 7.7% 11.9% 14.9% 7.4% -1.7%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 0.06
0.04
0.14
0.78
1.93
1.51
5.31
7.21
7.35
10.54
growth rate -25.5% 231.7% 473.5% 147.4% -21.9% 252.4% 35.8% 2.0% 43.3%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA -21.35
26.67
95.24
-33.60
-79.76
64.37
-5.00
growth rate 100.0% 257.2% -100.0% 0.0% 100.0% -100.0%
FCF per Share -0.41
-0.68
0.57
2.49
-1.06
-1.50
0.97
-0.95
growth rate 0.0% 100.0% 336.8% -100.0% 0.0% 100.0% -100.0%
Sale Purchase of Stock -8.00
0.32
124.08
128.25
3.73
254.24
10.66
18.04
growth rate 100.0% 39,166.8% 3.4% -97.1% 6,710.6% -95.8% 69.2%
FCF -3.00
-12.00
-7.00
-24.00
23.00
92.00
-41.00
-89.00
53.00
-19.00
growth rate 0.0% 0.0% 0.0% 100.0% 300.0% -100.0% 0.0% 100.0% -100.0%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 6.85
9.52
10.20
9.52
27.76
109.02
46.15
40.60
156.70
122.69
growth rate 39.1% 7.1% -6.7% 191.6% 292.7% -57.7% -12.0% 285.9% -21.7%
Op.Income -11.20
-8.59
-60.30
-15.95
-17.09
44.40
-42.73
-79.13
14.05
-76.26
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0% 100.0% -100.0%
IBT -11.20
-8.59
-60.30
-16.42
-17.59
46.12
-38.95
-70.41
27.19
-69.33
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0% 100.0% -100.0%
Net Income -11.20
-8.59
-60.30
-16.42
-17.59
45.13
-38.49
-70.41
26.88
-69.33
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0% 100.0% -100.0%
EPS -0.67
-0.51
-3.85
-0.52
-0.45
1.07
-0.82
-1.31
0.46
-1.21
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0% 100.0% -100.0%
Gross Profit 6.85
9.52
10.20
-9.00
-6.38
57.15
-25.62
-56.90
38.11
-47.11
growth rate 39.1% 7.1% -100.0% 0.0% 100.0% -100.0% 0.0% 100.0% -100.0%
R&D 12.66
12.67
17.00
71.77
71.77
71.77
71.77
97.50
118.59
169.80
growth rate 0.0% 34.2% 322.2% 0.0% 0.0% 0.0% 35.9% 21.6% 43.2%

Quarterly Statements

Item Name Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Earnings BIT -29.35
-8.78
-37.60
-16.72
-13.16
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Acct.Receivable 22.08
7.73
9.73
9.53
23.94
growth rate -65.0% 25.9% -2.0% 151.1%
Acct.Payable 19.18
10.31
10.51
13.11
8.95
growth rate -46.2% 1.9% 24.7% -31.7%
Cur.Assets 558.41
588.11
603.39
570.88
637.67
growth rate 5.3% 2.6% -5.4% 11.7%
Total Assets 670.25
666.96
644.72
646.35
703.24
growth rate -0.5% -3.3% 0.3% 8.8%
Cash 50.31
73.81
109.53
58.09
163.54
growth rate 46.7% 48.4% -47.0% 181.5%
Inventory
growth rate
Cur.Liabilities 66.56
65.92
66.45
70.49
121.06
growth rate -1.0% 0.8% 6.1% 71.8%
Liabilities 77.05
73.96
74.08
77.87
130.80
growth rate -4.0% 0.2% 5.1% 68.0%
LT Debt
growth rate
Equity 593.20
593.01
570.65
568.48
572.44
growth rate 0.0% -3.8% -0.4% 0.7%
Common Shares 56.90
0.57
0.57
0.57
0.58
growth rate -99.0% 0.4% 0.2% 1.2%
Cash Flow Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Capital Expenditures 2.91
2.07
0.62
4.70
3.15
growth rate -28.8% -70.0% 654.8% -32.9%
Cash Dividends
growth rate
Cash From OA -19.58
9.46
-27.68
-3.87
17.08
growth rate 100.0% -100.0% 0.0% 100.0%
Sale Purchase of Stock 2.97
1.47
4.00
2.99
growth rate -50.5% 171.9% -25.4%
FCF -22.49
7.39
-28.30
-8.56
13.94
growth rate 100.0% -100.0% 0.0% 100.0%
Income Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Sales 3.52
32.39
13.09
35.37
41.85
growth rate 821.1% -59.6% 170.2% 18.4%
Op.Income -30.57
-8.78
-37.60
-16.72
-13.16
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -27.20
-8.07
-35.02
-12.55
-13.69
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -26.91
-8.07
-35.02
-12.55
-13.69
growth rate 0.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 3.52
-1.56
-30.37
-9.09
-6.10
growth rate -100.0% 0.0% 0.0% 0.0%
R&D 27.34
33.94
43.46
44.45
growth rate 24.2% 28.0% 2.3%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (2.26)

YOY Growth Grade:

F (8.46)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -22.93 -27.25 -17.36
EPS / Growth 0.0% -1.65

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 21.1%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 10.6% 10.6%
Future PE 0.00 0.01 7.05
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.